Skip to content

US · PLRZ · BIOTECHNOLOGY

Polyrizon Ltd. (PLRZ) intrinsic value and stock valuation

$9.31as of 2026-11-21 · Mkt cap 12.6M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Polyrizon Ltd. DCF and intrinsic value

InvestorsCraft values PLRZ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PLRZ’s statements →

Polyrizon Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ra'anana, TA 4366507 polyrizon-biotech.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-3.33M
20202025
Free cash flow
-$-4.54M
20202025
Total equity
$21M+302% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-6.25M-$-1.3M-$-640K-$-900K-$-700K
Net income-$-3.33M-$-1.54M-$-600K-$-780K-$-710K
EPSd-$-2.07M-$-154M———
Operating cash flow-$-4.53M-$-1.15M-$-540K-$-1.13M-$-490K
Capital expenditure-$-10K$0.00$0.00-$0.00-$-20K
Free cash flow-$-4.54M-$-1.15M-$-540K-$-1.14M-$-510K
Total assets$21.4M$5.55M$560K$550K$690K
Total debt$0.00$0.00$200K$0.00$0.00
Net debt-$-1.31M-$-2.55M$200K-$-40K-$-520K
Total equity$21M$5.29M$60K-$-650K-$0.00
Cash and short-term investments$12.3M$2.55M$40K$40K$520K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$340K$120K$0.00$10K$10K
Gross profit-$-340K-$-120K-$0.00-$-10K-$-10K
Research and development expenses$2.13M$530K$330K$350K$240K
Selling, general and administrative expenses$3.77M$770K$300K$550K$450K
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$5.91M$1.3M$640K$900K$700K
Cost and expenses$6.25M$1.3M$640K$900K-$-700K
Interest income$370K$0.00$0.00$0.00$0.00
Interest expense$3.14M$0.00$0.00$0.00$0.00
Depreciation and amortization$340K$120K$0.00$10K$10K
Ebitda-$-5.91M-$-1.42M-$-630K-$-770K-$-700K
Operating income-$-6.25M-$-1.3M-$-640K-$-900K-$-700K
Total other income/expenses, net$2.91M-$-240K$40K$120K-$-10K
Income before tax-$-3.33M-$-1.54M-$-600K-$-780K-$-710K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3.33M-$-1.54M-$-600K-$-780K-$-710K
Weighted average shares outstanding$1.61M$10K$0.00$0.00$0.00
Weighted average diluted shares outstanding$1.61M$10K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$12.3M$2.55M$40K$40K$520K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$12.9M$2.65M$50K$50K$540K
Property, plant and equipment, net$10K$10K$10K$20K$20K
Goodwill and intangible assets$2.55M$2.88M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.58M$2.89M$510K$490K$140K
Total assets$21.4M$5.55M$560K$550K$690K
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$0.00$0.00$200K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$440K$260K$500K$1.2M$690K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$250K$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$440K$260K$750K$1.2M$690K
Common stock$0.00$0.00$0.00$0.00$330K
Retained earnings-$-8.4M-$-5.07M-$-3.52M-$-2.92M-$-2.14M
Accumulated other comprehensive income (loss)$0.00$0.00-$-200K$0.00$0.00
Total equity$21M$5.29M$60K-$-650K-$0.00
Total investments$11M$0.00$40K$0.00$0.00
Total debt$0.00$0.00$200K$0.00$0.00
Net debt-$-1.31M-$-2.55M$200K-$-40K-$-520K
Cash flow statement
20252024202320222021
Net income-$-3.33M-$-1.54M-$-600K-$-780K-$-710K
Depreciation and amortization$340K$120K$0.00$10K$10K
Stock-based compensation$0.00$50K$100K$130K$180K
Change in working capital-$-160K-$-20K$10K-$-340K$30K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-4.53M-$-1.15M-$-540K-$-1.13M-$-490K
Investments in property, plant and equipment-$-6.01M$0.00$0.00-$0.00-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-16.53M$30K$0.00-$0.00-$-20K
Common stock issued$19.8M$3.67M$260K$650K$1.02M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.8M$3.67M$510K$650K$1.02M
Net change in cash-$-1.25M$2.55M-$-30K-$-490K$510K
Cash at end of period$1.31M$2.55M$0.00$40K$520K
Operating cash flow-$-4.53M-$-1.15M-$-540K-$-1.13M-$-490K
Capital expenditure-$-10K$0.00$0.00-$0.00-$-20K
Free cash flow-$-4.54M-$-1.15M-$-540K-$-1.14M-$-510K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Polyrizon Ltd.

        Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

        CEO
        Tomer Izraeli
        Employees
        6
        Beta
        -1.53

        Explore

        Frequently asked questions

        What is the intrinsic value of Polyrizon Ltd. (PLRZ)?

        InvestorsCraft does not currently publish an intrinsic value for PLRZ. How the IC value is calculated.

        Is PLRZ undervalued?

        InvestorsCraft does not publish an undervaluation signal for PLRZ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.